Venrock

AIRNA is a biotechnology company specializing in the development of RNA editing therapies. Its platform enables the creation of therapeutics designed to treat both rare and common diseases, with the goal of improving patients' health.

Averto Medical is a manufacturer of medical devices focused on addressing gastrointestinal diseases. The company specializes in developing innovative solutions designed to facilitate minimally invasive colorectal tumor removal, which aims to reduce the need for multiple surgical procedures and associated complications. By providing effective medical care options for patients suffering from gastrointestinal disorders, Averto Medical seeks to improve patient outcomes and streamline treatment processes in this critical area of healthcare.

Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Tenaya Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative therapies for heart disease, particularly heart failure. Established in 2016, the company employs three main platforms to address the underlying causes of heart disease: a cellular regeneration platform that reprograms cardiac fibroblasts into cardiomyocytes using proprietary transcription factors, a gene therapy platform for targeted delivery of therapeutic payloads, and a precision medicine approach tailored to individual patients. Through these platforms, Tenaya Therapeutics aims to enable the regeneration of heart tissue and tackle various forms of cardiomyopathies, leveraging advanced research in cardiac development and regeneration.

Accompany Health is a health technology platform that delivers comprehensive in-home care to patients, particularly in underserved regions. The company focuses on providing primary care services, including chronic illness management and treatment of new symptoms. It aims to support low-income patients with complex health needs throughout their care journeys, offering both at-home and virtual services. By fostering long-term relationships with patients, Accompany Health ensures that individuals receive continuous support, with access to care available at all hours. This approach eliminates the need for waiting rooms and enhances the overall patient experience by emphasizing dignity and accessibility in healthcare.

Aledade, Inc. is a company that supports primary care physicians in establishing and managing accountable care organizations (ACOs) across the United States. Founded in 2014 and headquartered in Bethesda, Maryland, Aledade provides a comprehensive suite of services including data analytics, guided workflows, regulatory expertise, and payer relationships. The company aims to empower independent primary care providers by offering customized solutions, operational support, and advanced technology to enhance practice efficiency and patient care. Aledade serves a diverse range of healthcare practices, including small and large practices, community health centers, and multispecialty groups. By facilitating better care delivery and reducing overall costs, Aledade helps physicians maintain their independence while improving health outcomes for their patients.

Pharvaris is a clinical-stage company dedicated to the discovery and development of therapies for rare diseases, particularly focusing on hereditary angioedema (HAE) and other conditions mediated by bradykinin. The company is advancing an oral bradykinin B2 receptor antagonist, with its lead candidate, PHA121, currently undergoing Phase 1 clinical trials. Pharvaris aims to provide new treatment options that offer alternatives to injected therapies for all sub-types of HAE. The company was co-founded by key individuals involved in the development of icatibant, a previously established treatment for HAE, ensuring a strong foundation in this therapeutic area.

The Public Health Company is focused on creating a global biosecurity platform that offers a Software as a Service (SaaS) solution for managing bio-risks within enterprises. Founded in 2020 and headquartered in Palo Alto, California, the company combines expert knowledge with advanced technology to provide a comprehensive approach to enterprise risk management. Its platform addresses various physical world threats, delivering actionable and predictive intelligence that enables dynamic risk management with exceptional speed and scale. The Public Health Company serves businesses, healthcare providers, and public health systems, positioning itself as a key player in enhancing public health and safety through innovative solutions.

Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The company provides a range of affordable health coverage options, including dental plans, doctor visits, and prescription insurance. By simplifying the enrollment process, Stride Health enables users to quickly select their most cost-effective health plans while also offering assistance from personal advisors to help navigate any complexities. Founded in 2013 and based in San Francisco, California, Stride Health was previously known as Covered, Inc. The company's mission is to make health insurance more accessible and manageable for those who may not have traditional employment benefits.

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Pacific Palisades, California, focused on developing precision therapies for genetically-defined cancers. The company specializes in mTOR inhibitors, particularly ABI-009, aimed at treating patients with alterations in the TSC1 or TSC2 genes, where existing mTOR inhibitors have limitations in pharmacology, drug delivery, or safety. Aadi's primary focus is on providing transformational therapies for patients with ultra-rare cancers, such as perivascular epithelioid cell tumors (PEComa). Since its founding in 2011, Aadi Bioscience has aimed to address significant unmet medical needs in oncology and related therapeutic areas.

The Public Health Company is focused on creating a global biosecurity platform that offers a Software as a Service (SaaS) solution for managing bio-risks within enterprises. Founded in 2020 and headquartered in Palo Alto, California, the company combines expert knowledge with advanced technology to provide a comprehensive approach to enterprise risk management. Its platform addresses various physical world threats, delivering actionable and predictive intelligence that enables dynamic risk management with exceptional speed and scale. The Public Health Company serves businesses, healthcare providers, and public health systems, positioning itself as a key player in enhancing public health and safety through innovative solutions.

Pharvaris is a clinical-stage company dedicated to the discovery and development of therapies for rare diseases, particularly focusing on hereditary angioedema (HAE) and other conditions mediated by bradykinin. The company is advancing an oral bradykinin B2 receptor antagonist, with its lead candidate, PHA121, currently undergoing Phase 1 clinical trials. Pharvaris aims to provide new treatment options that offer alternatives to injected therapies for all sub-types of HAE. The company was co-founded by key individuals involved in the development of icatibant, a previously established treatment for HAE, ensuring a strong foundation in this therapeutic area.

CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in implantable technology for treating high blood pressure and heart failure. The company develops Barostim, a proprietary neuromodulation therapy that activates the body's natural reflexes to regulate blood pressure and address the progression of heart failure. This therapy is delivered through a long-lasting implant system that is tailored to meet individual patient needs. CVRx also manufactures the Rheos implantable pulse generator and associated components, which facilitate the delivery of activation energy to the carotid arteries. Founded in 2000, CVRx primarily serves patients and healthcare professionals in the United States and several European countries, focusing on minimally invasive solutions for cardiovascular diseases.

Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Devoted Health, established in 2017 and headquartered in Newton, Massachusetts, specializes in providing comprehensive healthcare solutions for Medicare beneficiaries in the United States. The company offers Medicare Advantage plans, along with personalized care through dedicated health guides, both in-person and virtually. Devoted Health aims to improve the health and well-being of older Americans by combining access to top local providers, virtual and in-home care through Devoted Medical, and advanced technology to deliver tailored healthcare experiences.

Virta Health Corp. is an online specialty medical clinic dedicated to reversing type 2 diabetes without the use of medications or surgery. Founded in 2014 and based in San Francisco, California, the company utilizes a combination of nutritional biochemistry, clinical expertise, data science, and digital solutions to deliver its innovative treatment. Through its continuous remote care platform, Virta provides extensive medical and behavioral support, which has shown significant results in clinical trials; 60% of enrolled patients achieved diabetes reversal after one year, while 94% of insulin users reduced or eliminated their insulin intake. The benefits of Virta's approach extend beyond diabetes, leading to improvements in blood pressure, inflammation, liver function, and body mass index (BMI), thereby transforming the lives of individuals affected by type 2 diabetes.

Pharvaris is a clinical-stage company dedicated to the discovery and development of therapies for rare diseases, particularly focusing on hereditary angioedema (HAE) and other conditions mediated by bradykinin. The company is advancing an oral bradykinin B2 receptor antagonist, with its lead candidate, PHA121, currently undergoing Phase 1 clinical trials. Pharvaris aims to provide new treatment options that offer alternatives to injected therapies for all sub-types of HAE. The company was co-founded by key individuals involved in the development of icatibant, a previously established treatment for HAE, ensuring a strong foundation in this therapeutic area.

Devoted Health, established in 2017 and headquartered in Newton, Massachusetts, specializes in providing comprehensive healthcare solutions for Medicare beneficiaries in the United States. The company offers Medicare Advantage plans, along with personalized care through dedicated health guides, both in-person and virtually. Devoted Health aims to improve the health and well-being of older Americans by combining access to top local providers, virtual and in-home care through Devoted Medical, and advanced technology to deliver tailored healthcare experiences.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which aims to modify a patient's hematopoietic stem cells to create a personalized treatment through a single administration. Orchard's product portfolio includes Strimvelis, the first gene therapy approved by the European Medicines Agency for adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company is advancing several clinical programs, including OTL-101 for ADA-SCID, OTL-200 for metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Additionally, Orchard has a robust preclinical pipeline targeting various mucopolysaccharidosis types. Founded in 2015, Orchard Therapeutics collaborates with leading institutions in the field to enhance its research and development efforts.

Virta Health Corp. is an online specialty medical clinic dedicated to reversing type 2 diabetes without the use of medications or surgery. Founded in 2014 and based in San Francisco, California, the company utilizes a combination of nutritional biochemistry, clinical expertise, data science, and digital solutions to deliver its innovative treatment. Through its continuous remote care platform, Virta provides extensive medical and behavioral support, which has shown significant results in clinical trials; 60% of enrolled patients achieved diabetes reversal after one year, while 94% of insulin users reduced or eliminated their insulin intake. The benefits of Virta's approach extend beyond diabetes, leading to improvements in blood pressure, inflammation, liver function, and body mass index (BMI), thereby transforming the lives of individuals affected by type 2 diabetes.

Aledade, Inc. is a company that supports primary care physicians in establishing and managing accountable care organizations (ACOs) across the United States. Founded in 2014 and headquartered in Bethesda, Maryland, Aledade provides a comprehensive suite of services including data analytics, guided workflows, regulatory expertise, and payer relationships. The company aims to empower independent primary care providers by offering customized solutions, operational support, and advanced technology to enhance practice efficiency and patient care. Aledade serves a diverse range of healthcare practices, including small and large practices, community health centers, and multispecialty groups. By facilitating better care delivery and reducing overall costs, Aledade helps physicians maintain their independence while improving health outcomes for their patients.

Devoted Health, established in 2017 and headquartered in Newton, Massachusetts, specializes in providing comprehensive healthcare solutions for Medicare beneficiaries in the United States. The company offers Medicare Advantage plans, along with personalized care through dedicated health guides, both in-person and virtually. Devoted Health aims to improve the health and well-being of older Americans by combining access to top local providers, virtual and in-home care through Devoted Medical, and advanced technology to deliver tailored healthcare experiences.

Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The company provides a range of affordable health coverage options, including dental plans, doctor visits, and prescription insurance. By simplifying the enrollment process, Stride Health enables users to quickly select their most cost-effective health plans while also offering assistance from personal advisors to help navigate any complexities. Founded in 2013 and based in San Francisco, California, Stride Health was previously known as Covered, Inc. The company's mission is to make health insurance more accessible and manageable for those who may not have traditional employment benefits.

Aledade, Inc. is a company that supports primary care physicians in establishing and managing accountable care organizations (ACOs) across the United States. Founded in 2014 and headquartered in Bethesda, Maryland, Aledade provides a comprehensive suite of services including data analytics, guided workflows, regulatory expertise, and payer relationships. The company aims to empower independent primary care providers by offering customized solutions, operational support, and advanced technology to enhance practice efficiency and patient care. Aledade serves a diverse range of healthcare practices, including small and large practices, community health centers, and multispecialty groups. By facilitating better care delivery and reducing overall costs, Aledade helps physicians maintain their independence while improving health outcomes for their patients.

Virta Health Corp. is an online specialty medical clinic dedicated to reversing type 2 diabetes without the use of medications or surgery. Founded in 2014 and based in San Francisco, California, the company utilizes a combination of nutritional biochemistry, clinical expertise, data science, and digital solutions to deliver its innovative treatment. Through its continuous remote care platform, Virta provides extensive medical and behavioral support, which has shown significant results in clinical trials; 60% of enrolled patients achieved diabetes reversal after one year, while 94% of insulin users reduced or eliminated their insulin intake. The benefits of Virta's approach extend beyond diabetes, leading to improvements in blood pressure, inflammation, liver function, and body mass index (BMI), thereby transforming the lives of individuals affected by type 2 diabetes.

Devoted Health, established in 2017 and headquartered in Newton, Massachusetts, specializes in providing comprehensive healthcare solutions for Medicare beneficiaries in the United States. The company offers Medicare Advantage plans, along with personalized care through dedicated health guides, both in-person and virtually. Devoted Health aims to improve the health and well-being of older Americans by combining access to top local providers, virtual and in-home care through Devoted Medical, and advanced technology to deliver tailored healthcare experiences.

Included Health is a healthcare company that provides a blend of virtual care, navigation, and community-based healthcare services to enhance the member experience. It combines advanced technology and a compassionate approach to deliver personalized care guidance and advocacy, ensuring that individuals receive the right care at the right time. The company's offerings include access to both virtual and in-person services for a range of healthcare needs, including urgent and primary care, behavioral health, and specialty care. By focusing on a member-centric model, Included Health aims to raise the standard of healthcare for everyone, making it simpler and more effective for individuals to navigate their health journey.

CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company based in South San Francisco, California. It specializes in developing a novel class of antibody therapeutics utilizing its Probody technology platform, which aims to enhance the targeting of tumors while minimizing drug activity in healthy tissues. The company's clinical-stage product candidates include CX-072, a therapeutic targeting programmed cell death ligand 1; CX-2009, a drug conjugate targeting CD166; BMS-986249 and BMS-986288, both targeting CTLA-4 for metastatic melanoma and solid tumors; and CX-2029, a drug conjugate for CD71 in solid tumors. CytomX collaborates strategically with several industry leaders, including AbbVie, Amgen, and Bristol-Myers Squibb, to advance its Probody therapeutics. Founded in 2008, CytomX Therapeutics is committed to providing innovative and less toxic treatment options for patients with severe illnesses such as cancer.

Aledade, Inc. is a company that supports primary care physicians in establishing and managing accountable care organizations (ACOs) across the United States. Founded in 2014 and headquartered in Bethesda, Maryland, Aledade provides a comprehensive suite of services including data analytics, guided workflows, regulatory expertise, and payer relationships. The company aims to empower independent primary care providers by offering customized solutions, operational support, and advanced technology to enhance practice efficiency and patient care. Aledade serves a diverse range of healthcare practices, including small and large practices, community health centers, and multispecialty groups. By facilitating better care delivery and reducing overall costs, Aledade helps physicians maintain their independence while improving health outcomes for their patients.

Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The company provides a range of affordable health coverage options, including dental plans, doctor visits, and prescription insurance. By simplifying the enrollment process, Stride Health enables users to quickly select their most cost-effective health plans while also offering assistance from personal advisors to help navigate any complexities. Founded in 2013 and based in San Francisco, California, Stride Health was previously known as Covered, Inc. The company's mission is to make health insurance more accessible and manageable for those who may not have traditional employment benefits.

Mevion Medical Systems, Inc. is a developer of proton therapy systems aimed at enhancing cancer treatment worldwide. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company has pioneered modern proton therapy technology. Its flagship product, the MEVION S250 Proton Therapy System, is designed to retain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating advanced patented technology, Mevion aims to improve beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment centers and clinicians globally.

Included Health is a healthcare company that provides a blend of virtual care, navigation, and community-based healthcare services to enhance the member experience. It combines advanced technology and a compassionate approach to deliver personalized care guidance and advocacy, ensuring that individuals receive the right care at the right time. The company's offerings include access to both virtual and in-person services for a range of healthcare needs, including urgent and primary care, behavioral health, and specialty care. By focusing on a member-centric model, Included Health aims to raise the standard of healthcare for everyone, making it simpler and more effective for individuals to navigate their health journey.

Aledade, Inc. is a company that supports primary care physicians in establishing and managing accountable care organizations (ACOs) across the United States. Founded in 2014 and headquartered in Bethesda, Maryland, Aledade provides a comprehensive suite of services including data analytics, guided workflows, regulatory expertise, and payer relationships. The company aims to empower independent primary care providers by offering customized solutions, operational support, and advanced technology to enhance practice efficiency and patient care. Aledade serves a diverse range of healthcare practices, including small and large practices, community health centers, and multispecialty groups. By facilitating better care delivery and reducing overall costs, Aledade helps physicians maintain their independence while improving health outcomes for their patients.

Mevion Medical Systems, Inc. is a developer of proton therapy systems aimed at enhancing cancer treatment worldwide. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company has pioneered modern proton therapy technology. Its flagship product, the MEVION S250 Proton Therapy System, is designed to retain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating advanced patented technology, Mevion aims to improve beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment centers and clinicians globally.

Included Health is a healthcare company that provides a blend of virtual care, navigation, and community-based healthcare services to enhance the member experience. It combines advanced technology and a compassionate approach to deliver personalized care guidance and advocacy, ensuring that individuals receive the right care at the right time. The company's offerings include access to both virtual and in-person services for a range of healthcare needs, including urgent and primary care, behavioral health, and specialty care. By focusing on a member-centric model, Included Health aims to raise the standard of healthcare for everyone, making it simpler and more effective for individuals to navigate their health journey.

Mevion Medical Systems, Inc. is a developer of proton therapy systems aimed at enhancing cancer treatment worldwide. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company has pioneered modern proton therapy technology. Its flagship product, the MEVION S250 Proton Therapy System, is designed to retain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating advanced patented technology, Mevion aims to improve beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment centers and clinicians globally.

Ariosa Diagnostics specializes in non-invasive prenatal screening services, primarily through its Harmony Prenatal Test. This test is designed to assess the risk of common fetal chromosome conditions by analyzing DNA from a simple blood sample taken from the pregnant woman. As one of the most extensively studied prenatal screening tests, the Harmony Prenatal Test offers a reliable method for informing expectant mothers about their fetus's health. Ariosa's proprietary technology enables precise analysis, making it a significant player in the field of prenatal diagnostics.

WorldHeart is a public company based in Salt Lake City, Utah, with additional offices in Oakland, California, and Herkenbosch, The Netherlands. The company focuses on the development and manufacturing of implantable ventricular assist devices (VADs) and mechanical circulatory support systems designed for both adults and children. WorldHeart specializes in a minimally invasive, magnetically levitated miniature rotary blood pump that aims to overcome significant challenges associated with existing VADs, such as stroke, bleeding, device failures, and the invasiveness of implantation procedures.

Ariosa Diagnostics specializes in non-invasive prenatal screening services, primarily through its Harmony Prenatal Test. This test is designed to assess the risk of common fetal chromosome conditions by analyzing DNA from a simple blood sample taken from the pregnant woman. As one of the most extensively studied prenatal screening tests, the Harmony Prenatal Test offers a reliable method for informing expectant mothers about their fetus's health. Ariosa's proprietary technology enables precise analysis, making it a significant player in the field of prenatal diagnostics.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.

Mevion Medical Systems, Inc. is a developer of proton therapy systems aimed at enhancing cancer treatment worldwide. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company has pioneered modern proton therapy technology. Its flagship product, the MEVION S250 Proton Therapy System, is designed to retain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating advanced patented technology, Mevion aims to improve beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment centers and clinicians globally.

Ariosa Diagnostics specializes in non-invasive prenatal screening services, primarily through its Harmony Prenatal Test. This test is designed to assess the risk of common fetal chromosome conditions by analyzing DNA from a simple blood sample taken from the pregnant woman. As one of the most extensively studied prenatal screening tests, the Harmony Prenatal Test offers a reliable method for informing expectant mothers about their fetus's health. Ariosa's proprietary technology enables precise analysis, making it a significant player in the field of prenatal diagnostics.

Mevion Medical Systems, Inc. is a developer of proton therapy systems aimed at enhancing cancer treatment worldwide. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company has pioneered modern proton therapy technology. Its flagship product, the MEVION S250 Proton Therapy System, is designed to retain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating advanced patented technology, Mevion aims to improve beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment centers and clinicians globally.

CodeRyte is a leading provider of computer-assisted coding and clinical data extraction solutions tailored for the healthcare industry. The company offers advanced software that automates the coding process and efficiently analyzes physician narratives to uncover critical clinical information. Their product suite includes CodeAssist, a web-based tool that streamlines coding by integrating with operational information systems, CodeComplete, an outsourced coding solution, and DataScout, which extracts valuable clinical data from both free-text and structured medical records. CodeRyte's technology helps healthcare providers improve reimbursement accuracy, enhance compliance, and boost operational efficiency, making it a trusted partner for numerous physician practices, billing companies, and academic medical centers across the nation.

CodeRyte is a leading provider of computer-assisted coding and clinical data extraction solutions tailored for the healthcare industry. The company offers advanced software that automates the coding process and efficiently analyzes physician narratives to uncover critical clinical information. Their product suite includes CodeAssist, a web-based tool that streamlines coding by integrating with operational information systems, CodeComplete, an outsourced coding solution, and DataScout, which extracts valuable clinical data from both free-text and structured medical records. CodeRyte's technology helps healthcare providers improve reimbursement accuracy, enhance compliance, and boost operational efficiency, making it a trusted partner for numerous physician practices, billing companies, and academic medical centers across the nation.

CardioThoracic Systems designs, develops, and manufactures surgical products and systems for minimally invasive cardiac surgery. The Company's current products are designed to enable the majority of cardiothoracic surgeons, using their existing skills coupled with company-sponsored training, to perform MICS on a beating heart. The OPCAB (Off Pump Coronary Artery Bypass) and MIDCAB (Minimally Invasive Direct Coronary Artery Bypass) procedures eliminate the need for a heart-lung machine, and recent studies indicate that the MICS procedures reduce the trauma, procedural costs and post-surgical complications associated with conventional coronary artery bypass graft (CABG) surgery while providing long-term procedural success rates comparable to CABG surgery. CardioThoracic Systems was founded in 1994 and is based in Cupertino, California. As of November 15, 1999, CardioThoracic Systems, Inc. was acquired by Guidant Corp.

Vical is a biopharmaceutical company that specializes in the development of DNA vaccines and non-viral gene therapies. Its core technology, which emerged from a serendipitous discovery, has paved the way for the establishment of two significant sectors within the industry. Vical has built a diverse portfolio of product development programs, both independently and in partnership with other organizations. The company has successfully launched its first products in the animal health market and is nearing the introduction of its initial human health products. Through systematic management and innovative research, Vical continues to advance its mission in the biopharmaceutical field.

CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company based in South San Francisco, California. It specializes in developing a novel class of antibody therapeutics utilizing its Probody technology platform, which aims to enhance the targeting of tumors while minimizing drug activity in healthy tissues. The company's clinical-stage product candidates include CX-072, a therapeutic targeting programmed cell death ligand 1; CX-2009, a drug conjugate targeting CD166; BMS-986249 and BMS-986288, both targeting CTLA-4 for metastatic melanoma and solid tumors; and CX-2029, a drug conjugate for CD71 in solid tumors. CytomX collaborates strategically with several industry leaders, including AbbVie, Amgen, and Bristol-Myers Squibb, to advance its Probody therapeutics. Founded in 2008, CytomX Therapeutics is committed to providing innovative and less toxic treatment options for patients with severe illnesses such as cancer.